Tenaya Therapeutics (TNYA) Announces Updates on TN-201 Gene Therapy Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA)
October 18, 2024 5:47 AM EDTLeerink Partners analyst Mani Foroohar reiterated an Outperform rating and $8.00 price target on Tenaya Therapeutics Inc (NASDAQ: TNYA)
The analyst comments "Bottom Line: After the close, TNYA shared updates on its Phase 1b/2 MyPEAK-1 trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy (MYBPC3-HCM). Cohort 1 (3E13 vg/kg, n=3 with first patient dosed in October 2023) showed a safety/tolerability profile... More
